Results 41 to 50 of about 13,127 (167)

Pharmacokinetic Interaction of Favipiravir with Citalopram and Pioglitazone

Journal of Pharmaceutical Research, 2022
The current study's objective was to investigate the interactions of favipiravir with pioglitazone and citalopram. 25 Spraque-Dawley female rats were used in the study.
Zeliha Keskin ​ Alkaç, Dilan Aşkın Özek, Hande Yüce, Fatih Ahmet Korkak, Sümeyye Aslan , Neşe Başak Türkmen, Songül Ünüvar   +6 more
doaj   +1 more source

Review of the Effects of Favipiravir on Filoviruses [PDF]

, 2020
Objective: a review of current studies on the efficacy of favipiravir as a treatment option for Ebola and Marburg viruses. Methods: Studies were gathered from several sources, including PubMed, JSTOR, and Science Direct.
Bladholm, Bailey
core   +1 more source

When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

Journal of Infection and Public Health, 2023
Background: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease.
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Mashael AlFaifi, Majed Nahari, Alaa Almagthali, Abrar K. Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A. Alenazi, Aisha Alharbi, Munirah M. Alghwainm, Sara M. Alotaibi, Yazeed S. Alghamdi, Samar Alotaibi, Shaden H. Alonazi, Jumanah M. Almutairi, Ramesh Vishwakarma   +19 more
doaj   +1 more source

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.: Favipiravir pharmacokinetics in non-human primates

, 2016
International audienceFavipiravir is a RNA polymerase inhibitor that showed a strong antiviral efficacy in vitro and in small animal models of several viruses responsible for hemorrhagic fever (HF) including Ebola virus.
Yamada, Koichi, Raoul, Hervé, Nguyen, Thi Huyen Tram, Jacquot, Frédéric, Guedj, Jérémie, Mentré, France, Oestereich, Lisa, Taburet, Anne-Marie, Kadota, Takumi, de Lamballerie, Xavier, Madelain, Vincent   +10 more
core   +1 more source

Favipiravir-induced inflammatory and hydropic degenerative liver injury in rats

, 2023
Background. Favipiravir is very effective in the treatment of many viral infections, especially at high doses. It was used at such doses to treat coronavirus disease 2019 (COVID-19) during the pandemic.
Halis Suleyman, BİLİCİ, SAMİ, Fikret Altindag, Cebrail Gursul, SÜLEYMAN, HALİS, ÖZÇİÇEK, ADALET, Mine Gulaboglu, GÜLABOĞLU, Mine, Bulut, Seval, Durdu Altuner, Zeynep Suleyman, Altindag, Fikret, Sarigul, Cengiz, SÜLEYMAN, ZEYNEP, Seval Bulut, GÜRSUL, CEBRAİL, Sami Bilici, Altındağ, Fikret, ALTUNER, DURDU, Cengiz Sarigul, Adalet Ozcicek   +20 more
core   +1 more source

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia

International Journal of Infectious Diseases, 2023
Objectives: To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. Methods: We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients ...
Mahoko Ikeda, Shu Okugawa, Kosuke Kashiwabara, Takashi Moritoyo, Yoshiaki Kanno, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Kenji Tsushima, Yasuki Uchida, Takahiro Mitsumura, Hidetoshi Igari, Takeya Tsutsumi, Hideki Araoka, Kazuhiro Yatera, Yoshihiro Yamamoto, Yuki Nakamura, Amato Otani, Marie Yamashita, Yuji Wakimoto, Takayuki Shinohara, Maho Adachi-Katayama, Tatsunori Oyabu, Aoi Kanematsu, Sohei Harada, Yuichiro Takeshita, Yasutaka Nakano, Yasunari Miyazaki, Seiichiro Sakao, Makoto Saito, Sho Ogura, Kei Yamasaki, Hitoshi Kawasuji, Osamu Hataji, Jun-Ichiro Inoue, Yasuyuki Seto, Kyoji Moriya   +36 more
doaj   +1 more source

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia

Frontiers in Medicine, 2022
ObjectivesThere are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase.
Saleh Al-Muhsen, Nouf S. Al-Numair, Narjes Saheb Sharif-Askari, Roaa Basamh, Banan Alyounes, Amjad Jabaan, Fatemeh Saheb Sharif-Askari, Mohammed F. Alosaimi, Fahad Alsohime, Rabih Halwani, Rabih Halwani, Rabih Halwani, Haya Al-Saud, Haya Al-Saud   +13 more
doaj   +1 more source

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

, 2018
BackgroundDespite repeated outbreaks, in particular the devastating 2014–2016 epidemic, there is no effective treatment validated for patients with Ebola virus disease (EVD).
Raoul, Hervé, Stephan Gunther (5018402), Jacquot, Frédéric, Géraldine Piorkowski (800529), France Mentré (238333), Gunther, Stephan, Géraldine Piorkowski, Piorkowski, Géraldine, Caroline Carbonnelle, Xavier de Lamballerie, Stephan Gunther, Carbonnelle, Caroline, France Mentré, Anne Rodallec (3776029), Mentré, France, Caroline Carbonnelle (2549053), Anne Rodallec, Thi Huyen Tram Nguyen, Thi Huyen Tram Nguyen (3776035), Hervé Raoul (288207), Nguyen, Thi Huyen Tram, Jérémie Guedj (2549236), Vincent Madelain, Rodallec, Anne, de Lamballerie, Xavier, Madelain, Vincent, Xavier de Lamballerie (95840), Vincent Madelain (3776032), Hervé Raoul, Guedj, Jérémie, Frédéric Jacquot (2825714), Jérémie Guedj, Frédéric Jacquot   +32 more
core   +1 more source

Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

São Paulo Medical Journal, 2022
BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option.
Figen Öztürk Ergür, Murat Yıldız, Melahat Uzel Şener, Suna Kavurgacı, Ayperi Ozturk   +4 more
doaj   +1 more source

The mechanism of resistance to favipiravir in influenza. [PDF]

, 2018
Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections. While emergence of resistance has been observed for many antiinfluenza drugs, to date, clinical trials and laboratory studies of favipiravir have
te Velthuis, Aartjan JW, Lackenby, Angie, Zambon, Maria, Goldhill, Daniel H, Fletcher, Robert A, Barclay, Wendy S, Langat, Pinky   +6 more
core   +3 more sources